136 related articles for article (PubMed ID: 37188917)
1. Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response.
Kirouac DC; Zmurchok C; Deyati A; Sicherman J; Bond C; Zandstra PW
Nat Biotechnol; 2023 Nov; 41(11):1655. PubMed ID: 37188917
[No Abstract] [Full Text] [Related]
2. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Mody H; Ogasawara K; Zhu X; Miles D; Shastri PN; Gokemeijer J; Liao MZ; Kasichayanula S; Yang TY; Chemuturi N; Gupta S; Jawa V; Upreti VV
Clin Pharmacol Ther; 2023 Sep; 114(3):530-557. PubMed ID: 37393588
[TBL] [Abstract][Full Text] [Related]
3. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method.
Tohka J; Reilhac A
Neuroimage; 2008 Feb; 39(4):1570-84. PubMed ID: 18077187
[TBL] [Abstract][Full Text] [Related]
4. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
5. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model.
Mueller-Schoell A; Puebla-Osorio N; Michelet R; Green MR; Künkele A; Huisinga W; Strati P; Chasen B; Neelapu SS; Yee C; Kloft C
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34205020
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of Chimeric Antigen Receptor-Modified T Cells.
Song EZ; Milone MC
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():805-829. PubMed ID: 33035447
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Dupouy S; Marchiq I; Derippe T; Almena-Carrasco M; Jozwik A; Fouliard S; Adimy Y; Geronimi J; Graham C; Jain N; Maus MV; Mohty M; Boissel N; Teshima T; Kato K; Benjamin R; Balandraud S
Cancer Res Commun; 2022 Nov; 2(11):1520-1531. PubMed ID: 36970059
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
9. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.
Kast J; Nozohouri S; Zhou D; Yago MR; Chen PW; Ahamadi M; Dutta S; Upreti VV
Clin Transl Sci; 2022 Sep; 15(9):2057-2074. PubMed ID: 35677992
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2021 Mar; 27(3):561. PubMed ID: 33547459
[No Abstract] [Full Text] [Related]
11. Partial volume effect correction in PET using regularized iterative deconvolution with variance control based on local topology.
Kirov AS; Piao JZ; Schmidtlein CR
Phys Med Biol; 2008 May; 53(10):2577-91. PubMed ID: 18441414
[TBL] [Abstract][Full Text] [Related]
12. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y
Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868
[TBL] [Abstract][Full Text] [Related]
13. Author Correction: Benchmarking of cell type deconvolution pipelines for transcriptomics data.
Cobos FA; Alquicira-Hernandez J; Powell JE; Mestdagh P; De Preter K
Nat Commun; 2020 Dec; 11(1):6291. PubMed ID: 33268785
[TBL] [Abstract][Full Text] [Related]
14. Septal penetration correction in I-131 imaging following thyroid cancer treatment.
Barrack F; Scuffham J; McQuaid S
Phys Med Biol; 2018 Mar; 63(7):075012. PubMed ID: 29465414
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
Xiang X; He Q; Ou Y; Wang W; Wu Y
Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
[No Abstract] [Full Text] [Related]
16. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis.
Zhao Z; Zhang J; Bian J; Lu X
Ann Transl Med; 2022 May; 10(9):508. PubMed ID: 35928759
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN; Lam N; Vanasse D; Shen YW; Rose JJ; Rossi J; Xue A; Bot A; Scholler N; Mikkilineni L; Roschewski M; Dean R; Cachau R; Youkharibache P; Patel R; Hansen B; Stroncek DF; Rosenberg SA; Gress RE; Kochenderfer JN
Nat Med; 2020 May; 26(5):803. PubMed ID: 32291416
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: Cellular deconvolution of GTEx tissues powers discovery of disease and cell-type associated regulatory variants.
Donovan MKR; D'Antonio-Chronowska A; D'Antonio M; Frazer KA
Nat Commun; 2020 Sep; 11(1):4426. PubMed ID: 32873812
[TBL] [Abstract][Full Text] [Related]
20. Correction: Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies.
Huang J; Alexey S; Li J; Jones T; Grande G; Douthit L; Xie J; Chen D; Wu X; Michael M; Xiao C; Zhao J; Xie X; Xie J; Chen XL; Fu G; Alexander G; Tzeng CM
Leukemia; 2019 Sep; 33(9):2341. PubMed ID: 31097784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
